Hyperion DeFi (NASDAQ:HYPD) and Alpha Tau Medical (NASDAQ:DRTSW) Head to Head Contrast

Hyperion DeFi (NASDAQ:HYPD) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider & Institutional Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Hyperion DeFi and Alpha Tau Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Alpha Tau Medical	N/A	N/A	N/A

Valuation & Earnings

This table compares Hyperion DeFi and Alpha Tau Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	65.51	-$45.31 million	($9.95)	-0.35
Alpha Tau Medical	N/A	N/A	N/A	N/A	N/A

Alpha Tau Medical has lower revenue, but higher earnings than Hyperion DeFi.

Analyst Ratings

This is a breakdown of current ratings for Hyperion DeFi and Alpha Tau Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	1	1	2.25
Alpha Tau Medical	0	0	0	0	0.00

Hyperion DeFi currently has a consensus price target of $5.88, suggesting a potential upside of 67.86%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, equities analysts plainly believe Hyperion DeFi is more favorable than Alpha Tau Medical.

Summary

Hyperion DeFi beats Alpha Tau Medical on 7 of the 9 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.